Company
Aveo Pharmaceuticals
Aveo Pharmaceuticals has 13 drugs tracked on RxWires: 2 in Phase 3, 2 in Phase 2/3, 2 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Tivozanib | Phase 3 | Renal Cell Carcinoma |
| Ficlatuzumab | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma |
| Samalizumab (BAML-16-001-S1) | Phase 2/3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia |
| Rilogrotug | Phase 2/3 | Cachexia; Cancer |
| Atezolizumab | Phase 1/2 | Bile Duct Cancer |
| AV-299 + gefitinib | Phase 1/2 | Carcinoma, Non-Small Cell-Lung |
| AV-412 | Phase 1 | Advanced Cancer |
| AV-299 | Phase 1 | Malignant Solid Tumor |
| tivozanib (AV-951) and capecitabine (Xeloda®) | Phase 1 | Advanced Solid Tumors |
| Tivozanib (AV-951) plus FOLFOX6 | Phase 1 | Colorectal Cancer |
| AV-380 | Phase 1 | Cachexia |
| tivozanib (AV-951) + paclitaxel | Phase 1 | Metastatic Breast Cancer |
| AV-203 | Phase 1 | Solid Tumors |
Latest
Follow Aveo Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.